Journal of Lipid Research · 2009 · 57 citations · 23 references
MedicineBiochemistryPharmacologyDrug MetabolismEnzymologyMolecular PharmacologyAntifungal AgentsCholesterol MetabolismCytochrome P450 EnzymesCytochrome P450-mediated MetabolismLipid MetabolismSteroidogenic EnzymesAntifungal Drug ResistanceCytochrome P450 Enzyme InhibitionCytochrome P450 Structure-function RelationshipsCytochrome P450-mediated HydroxylationCytochrome P450-mediated Steroid MetabolismHmg-coa Reductase InhibitorsInhibitor SelectivityPharmacological Inhibition Of Cholesterol Biosynthesis
Cholesterol 24S-hydroxylase (CYP46A1) is of key importance for cholesterol homeostasis in the brain. This enzyme seems to be resistant toward most regulatory factors and at present no drug effects on its activity have been described. The crystal structures of the substrate-free and substrate-bound CYP46A1 were recently determined (Mast et al., Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc. Natl. Acad. Sci. USA. 2008. 105: 9546–9551). These structural studies suggested that ligands other than sterols can bind to CYP46A1. We show here that the antifungal drug voriconazole binds to the enzyme in vitro and inhibits CYP46A1-mediated cholesterol 24-hydroxylation with a Ki of 11 nM. Mice treated with daily intraperitoneal injections of voriconazole for 5 days had high levels of voriconazole in the brain and significantly reduced brain levels of 24S-hydroxycholesterol. The levels of squalene, lathosterol, and HMG-CoA reductase mRNA were reduced in the brain of the voriconazole-treated animals as well, indicating a reduced cholesterol synthesis. Most of this effect may be due to a reduced utilization of cholesterol by CYP46A1. One of the side-effects of voriconazole is visual disturbances. Because CYP46A1 is also expressed in the neural retina, we discuss the possibility that the inhibition of CYP46A1 by voriconazole contributes to these visual disturbances. Cholesterol 24S-hydroxylase (CYP46A1) is of key importance for cholesterol homeostasis in the brain. This enzyme seems to be resistant toward most regulatory factors and at present no drug effects on its activity have been described. The crystal structures of the substrate-free and substrate-bound CYP46A1 were recently determined (Mast et al., Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc. Natl. Acad. Sci. USA. 2008. 105: 9546–9551). These structural studies suggested that ligands other than sterols can bind to CYP46A1. We show here that the antifungal drug voriconazole binds to the enzyme in vitro and inhibits CYP46A1-mediated cholesterol 24-hydroxylation with a Ki of 11 nM. Mice treated with daily intraperitoneal injections of voriconazole for 5 days had high levels of voriconazole in the brain and significantly reduced brain levels of 24S-hydroxycholesterol. The levels of squalene, lathosterol, and HMG-CoA reductase mRNA were reduced in the brain of the voriconazole-treated animals as well, indicating a reduced cholesterol synthesis. Most of this effect may be due to a reduced utilization of cholesterol by CYP46A1. One of the side-effects of voriconazole is visual disturbances. Because CYP46A1 is also expressed in the neural retina, we discuss the possibility that the inhibition of CYP46A1 by voriconazole contributes to these visual disturbances. Cholesterol 24S-hydroxylase (CYP46A1) is of key importance for cholesterol homeostasis in the brain and is responsible for about two-thirds of cholesterol elimination from this organ (1Björkhem I. Lutjohann D. Breuer O. Sakinis A. Wennmalm A. Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro.J. Biol. Chem. 1997; 272: 30178-30184Abstract Full Text Full Text PDF PubMed Scopus (236) Google Scholar, 2Lund E.G. Xie C. Kotti T. Turley S.D. Dietschy J.M. Russell D.W. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover.J. Biol. Chem. 2003; 278: 22980-22988Abstract Full Text Full Text PDF PubMed Scopus (281) Google Scholar). Except for the enzyme induction during neonatal stage and a stimulatory effect by oxidative stress, CYP46A1 appeared to be resistant toward a broad spectrum of factors expected to regulate at transcriptional level (3Ohyama Y. Meaney S. Heverin M. Ekstrom L. Brafman A. Shafir M. Andersson U. Olin M. Eggertsen G. Diczfalusy U. et al.Studies on the transcriptional regulation of cholesterol 24- hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes.J. Biol. Chem. 2006; 281: 3810-3820Abstract Full Text Full Text PDF PubMed Scopus (103) Google Scholar). Very recently, the enzyme was crystallized in substrate-free and substrate-bound forms and found to undergo conformational changes upon substrate binding (4Mast N. White M.A. Björkhem I. Johnson E.F. Stout C.D. Pikuleva I.A. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.Proc. Natl. Acad. Sci. USA. 2008; 105: 9546-9551Crossref PubMed Scopus (100) Google Scholar). This conformational flexibility of the active site prompted us to screen more than 50 different compounds for their binding and inhibition of CYP46A1. Several marketed drugs and nonpharmaceuticals were found to bind tightly to the active site and inhibit CYP46A1 activity in vitro (4Mast N. White M.A. Björkhem I. Johnson E.F. Stout C.D. Pikuleva I.A. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.Proc. Natl. Acad. Sci. USA. 2008; 105: 9546-9551Crossref PubMed Scopus (100) Google Scholar). Of the eight strong CYP46A1 inhibitors identified in that study, five were imidazole-containing compounds: the H2-receptor antagonist cimetidine, the H3-receptor antagonist clobenpropit, the H3/H4 receptor antagonist thioperamide, nonpharmaceutical 4-(4-chlorophenyl)-imidazole, and the antifungal azole clotrimazole. The latter is applied only topically, therefore, in the present study we tested whether antifungal azoles that are administered systemically can inhibit CYP46A1 (Fig. 1). These drugs are known to pass the blood-brain barrier and thus have a potential to inhibit CYP46A1, which is localized almost exclusively to the brain in humans. We demonstrate here that voriconazole is an effective inhibitor of CYP46A1 in vitro and that intraperitoneal injections of the drug in mice reduce the levels of 24S- hydroxycholesterol in the brain. This finding is discussed in relation to the known side-effects of voriconazole. Voriconazole (vFEND) for in vitro studies was obtained from Pfizer. Aqueous solution of methanol (50%) was used to dissolve the compound. Voriconazole for the animal studies was a generous gift from the Division of Clinical Pharmacology at Karolinska University Hospital in Huddinge, Sweden. The material was dissolved in a mixture of saline containing 10% ethanol and 1% serum albumin. The final concentration of voriconazole was 100 mg/ml. Recombinant full-length human CYPs 46A1 and 27A1 and bovine CYP11A1 were expressed and purified as described (5Mast N. Norcross R. Andersson U. Shou M. Nakayama K. Björkhem I. Pikuleva I.A. Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain.Biochemistry. 2003; 42: 14284-14292Crossref PubMed Scopus (96) Google Scholar, 6Murtazina D.A. Andersson U. Hahn I.S. Björkhem I. Ansari G.A. Pikuleva I.A. Phospholipids modify substrate binding and enzyme activity of human cytochrome P450 27A1.J. Lipid Res. 2004; 45: 2345-2353Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar, 7Pikuleva I.A. Puchkaev A. Björkhem I. Putative helix F contributes to regioselectivity of hydroxylation in mitochondrial cytochrome P450 27A1.Biochemistry. 2001; 40: 7621-7629Crossref PubMed Scopus (35) Google Scholar). Binding affinities of antifungal drugs were estimated as described (5Mast N. Norcross R. Andersson U. Shou M. Nakayama K. Björkhem I. Pikuleva I.A. Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain.Biochemistry. 2003; 42: 14284-14292Crossref PubMed Scopus (96) Google Scholar, 8Mast N. Andersson U. Nakayama K. Björkhem I. Pikuleva I.A. Expression of human cytochrome P450 46A1 in Escherichia coli: effects of N- and C-terminal modifications.Arch. Biochem. Biophys. 2004; 428: 99-108Crossref PubMed Scopus (36) Google Scholar) using 0.3 μM purified P450. Titrations of CYP46A1 were carried out in 50 mM potassium phosphate buffer (KPi), pH 7.2, containing 100 mM NaCl and 0.02% Cymal 6. CYPs 11A1 and 27A1 were in 50 mM KPi without any additives. Antifungal drugs were added from 0.2–5 mM stocks in 50% methanol. The apparent Kd and maximal absorbance change were estimated by nonlinear least-squares fitting using the quadratic form of the single-site binding equation (9Copeland R.A. Protein-ligand binding equilibria.in: Copeland R.A. Enzymes. A John Wiley & Sons, Inc, New York2000: 76-108Crossref Google Scholar). Cholesterol hydroxylation by CYP46A1 was assayed for 20 min at 37°C in 1 ml of 50 mM KPi, pH 7.2, containing 100 mM NaCl, 0.02% Cymal 6, 40 μg dilauroylglycerol-3-phosphatidylcholine, and 2U of catalase. Purified 0.4 μM CYP46A1 was reconstituted with 0.8 μM NADPH cytochrome P450 oxidoreductase, 5.4 μM cholesterol, trace amounts of [3H]cholesterol (250,000 cpm), and varying concentrations of voriconazole (from 0.000001 μM to 100 μM). The enzymatic reaction was initiated by NADPH (final 1 mM) and terminated by vortexing with 2 ml of CH2Cl2. The organic phase was isolated, evaporated, dissolved in methanol, and subjected to HPLC as described (8Mast N. Andersson U. Nakayama K. Björkhem I. Pikuleva I.A. Expression of human cytochrome P450 46A1 in Escherichia coli: effects of N- and C-terminal modifications.Arch. Biochem. Biophys. 2004; 428: 99-108Crossref PubMed Scopus (36) Google Scholar). To determine IC50, data were fit to the following equation by Graph-Pad Prism software: %ControlActivity=100•(A−(B·II+IC50)), in which I is the inhibitor concentration, the IC50 represents the inflection point and the value of 1−(A−B) is the maximum inhibition observed at an infinite inhibitor concentration. Under the assay conditions used, two types of products were formed, 24-hydroxycholesterol and 24, 25- and 24, 27-dihydroxycholesterols, which are produced upon further hydroxylation of 24- hydroxycholesterol. Dihydroxycholesterols were eluted as one peak during HPLC; therefore, we could estimate two IC50 values, one for the inhibition of cholesterol 24-hydroxylation and the other for the inhibition of 25- and 27-hydroxylations of 24S-hydroxycholesterol. In addition, we could also estimate the Ki for cholesterol 24-hydroxylation assuming a model of competitive inhibition. Determination of IC50 was carried out at cholesterol concentration equal to Km, therefore Ki = IC50/2. Seven-week-old male C57/B6 J mice from Charles River were injected intraperitoneally with voriconazole (60 mg/kg or 75 mg/kg, corresponding to 0.6 and 0.75 ml, respectively, of the drug solution). The control mice were injected with the same solutions containing no voriconazole. The mice were euthanized by cervical dislocation. Brain and liver were collected, snap- frozen in liquid nitrogen, and stored at −80°C until further analysis. Lipids were extracted from the brain according to Folch with some modifications (10Folch J. Lees M. Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues.J. Biol. Chem. 1957; 226: 497-509Abstract Full Text PDF PubMed Google Scholar, 11Folch J. Ascoli I. Lees M. Meath J.A. Le B.N. Preparation of lipide extracts from brain tissue.J. Biol. Chem. 1951; 191: 833-841Abstract Full Text PDF PubMed Google Scholar). Approximately 10 mg of brain tissue was added to 1 ml of homogenization buffer (5 mM EDTA, 50 μg/ml butylated hydroxytoluene in phosphate-buffered saline, pH 7,4) in a clean glass tube and the tissue was disrupted using a polytron homogenizer. Three milliliters of chloroform-methanol (2:1, v/v) were added to the homogenate and the vials were mixed by vortexing. Samples were centrifuged at 10,000 g for 10 min. The organic phase was transferred to a new vial. The aqueous phase was reextracted as described previously three more times. The pooled organic phase was dried under a stream of argon gas, and chloroform-methanol (2:1, v/v) added to the dried samples to achieve suitable concentration. Sterols were analyzed by isotope dilution mass-spectrometry as previously described (3Ohyama Y. Meaney S. Heverin M. Ekstrom L. Brafman A. Shafir M. Andersson U. Olin M. Eggertsen G. Diczfalusy U. et al.Studies on the transcriptional regulation of cholesterol 24- hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes.J. Biol. Chem. 2006; 281: 3810-3820Abstract Full Text Full Text PDF PubMed Scopus (103) Google Scholar, 12Dzeletovic S. Breuer O. Lund E. Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry.Anal. Biochem. 1995; 225: 73-80Crossref PubMed Scopus (456) Google Scholar, 13Heverin M. Bogdanovic N. Lutjohann D. Bayer T. Pikuleva I. Bretillon L. Diczfalusy U. Winblad B. Björkhem I. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease.J. Lipid Res. 2004; 45: 186-193Abstract Full Text Full Text PDF PubMed Scopus (234) Google Scholar, 14Björkhem I. Lutjohann D. Diczfalusy U. Stahle L. Ahlborg G. Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation.J. Lipid Res. 1998; 39: 1594-1600Abstract Full Text Full Text PDF PubMed Google Scholar). Cholesterol was determined after saponification using [2H6] cholesterol as internal standard; [2H3] lathosterol was used as internal standard for quantification of lathosterol. 24S-Hydroxycholesterol and 27-hydroxycholesterol in the brain were measured by GC-MS (3Ohyama Y. Meaney S. Heverin M. Ekstrom L. Brafman A. Shafir M. Andersson U. Olin M. Eggertsen G. Diczfalusy U. et al.Studies on the transcriptional regulation of cholesterol 24- hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes.J. Biol. Chem. 2006; 281: 3810-3820Abstract Full Text Full Text PDF PubMed Scopus (103) Google Scholar, 12Dzeletovic S. Breuer O. Lund E. Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry.Anal. Biochem. 1995; 225: 73-80Crossref PubMed Scopus (456) Google Scholar) as are squalene, lanosterol, and dehydrolanosterol (15Tamboli I.Y. Prager K. Thelen K.M. Dewachter I. Pietrzik C.U. St George-Hyslop P. Sisodia S.S. De Srooper B. Heneka M.T. Filippov M.A. et al.Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis.J. Neurosci. 2008; 28: 12097-12106Crossref PubMed Scopus (54) Google Scholar). Voriconazole was determined in serum and brain homogenates after the extraction with chloroform-methanol (2:1, v/v) and ethanol (10%, v/v, final), respectively. Voriconazole extract (100 μl) was then mixed with 200 μl acetonitrile, centrifuged at 10,000 g for 10 min, and 1 μl of the supernatant injected onto a Phenomenex Luna C18 3 μm column (100 × 2 mm) connected to the Agilent 1100 liquid chromatography-mass spectrometry system with an autosampler and solvent degasser. Gradient elution was with initial 35% B increasing to 100% B in 5 min (A = 1% acetonitrile with 25 mM formic acid; B = 100% acetonitrile with 25 mM formic acid). A structure analog (UK115794, Pfizer Ltd.) was used as internal standard. Ions were monitored in a positive mode at m/z 350 (voriconazole) and m/z 348 (internal standard). Total RNA was obtained from brain and liver tissue using was from 2 μg of total RNA using mRNA levels were estimated using on were on an Prism of a gene was using the method using as data is expressed as of gene data using and the 2001; PubMed Scopus Google Scholar). are also as a was in vitro were in animal from the animal antifungal azoles that are used systemically were and (Fig. 1 and 1). Of voriconazole had the to CYP46A1, to that of with the estimated Kd value of 50 nM. Voriconazole a with a at and a maximum at (Fig. This that voriconazole binds to the CYP46A1 active site and the P450 with one of its Andersson M. of cytochrome of the to in the Biol. Chem. Full Text PDF PubMed Google Scholar, Crystal structures of and of cytochrome PubMed Scopus Google Scholar). CYP46A1 is the only enzyme expressed in the brain. present in the brain are which cholesterol and which cholesterol to J. C. S. D. N. J.M. D. J. K. et of cholesterol in Alzheimer's disease.J. Biol. Chem. 2004; Full Text Full Text PDF PubMed Scopus Google Scholar, B. in the human J. 2001; PubMed Scopus Google Scholar). We tested voriconazole on these as to CYP46A1, voriconazole a in its binding was than that to CYP46A1 as by the apparent Kd equal to In only a was indicating that voriconazole bind to the enzyme at the concentrations to 100 or the drug is in the P450 active site in the of the of antifungal azoles to on the of the The the of three different to of of a is used This data is from was absorbance 0.3 μM P450 was with to a 100 μM on the of the The the of three different to of is used This data is from (4Mast N. White M.A. Björkhem I. Johnson E.F. Stout C.D. Pikuleva I.A. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.Proc. Natl. Acad. Sci. USA. 2008; 105: 9546-9551Crossref PubMed Scopus (100) Google The was absorbance 0.3 μM P450 was with to a 100 μM in a new Of the three CYP46A1 the binding of voriconazole. we tested whether voriconazole inhibits the enzyme activity in CYP46A1 cholesterol to 24S-hydroxycholesterol and then can further 24S-hydroxycholesterol to 24, and (5Mast N. Norcross R. Andersson U. Shou M. Nakayama K. Björkhem I. Pikuleva I.A. Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain.Biochemistry. 2003; 42: 14284-14292Crossref PubMed Scopus (96) Google Scholar). The IC50 for cholesterol 24-hydroxylation was and that for 25- and 27-hydroxylations of 24S-hydroxycholesterol was (Fig. Because cholesterol concentration in the inhibition assay was equal to the Km, the Ki for cholesterol 24-hydroxylation was estimated to be 11 nM. In a study, we mice to different of euthanized and control animals after the and measured the levels of 24S-hydroxycholesterol in the brain. The appeared to reduce the levels of 24S-hydroxycholesterol. The levels were after the with mg/kg than after with 75 mg/kg In a we treated five mice with mg/kg and euthanized the animals and their 2 The levels of 24S-hydroxycholesterol were reduced by this effect was was no effect on levels of lathosterol or total cholesterol in the brain we treated mice with mg/kg a for 5 days and observed a in the levels of 24S-hydroxycholesterol = (Fig. was no effect on the levels of cholesterol (Fig. or 27-hydroxycholesterol (Fig. the level of lathosterol in the brain was significantly reduced (Fig. as a for cholesterol E. L. E. I. Determination of serum levels of lathosterol by isotope dilution-mass J. PubMed Scopus Google Scholar). reduced levels of this in voriconazole-treated mice a in cholesterol Because most of the 24S-hydroxycholesterol present in the from the a of brain to a of plasma voriconazole an effect on the in the A of plasma from the voriconazole-treated mice had a concentration of 24S- hydroxycholesterol of A of plasma from the control mice had a concentration of 24S-hydroxycholesterol of voriconazole appeared to the plasma levels by about be out that the plasma level of 27-hydroxycholesterol was significantly by the voriconazole This oxysterol was at and in the voriconazole-treated mice and in the respectively. The reduced levels of lathosterol in the voriconazole-treated mice a reduced cholesterol synthesis. of this could be due to the inhibition of the cytochrome P450 enzyme which is responsible for of lanosterol, an of lathosterol. In with we found that the brain levels of from tissue in the to 10 tissue in the voriconazole-treated mice The levels of were tissue and respectively. The levels of a were 0.8 tissue in the and 0.6 tissue in the voriconazole-treated mice = The latter is with a of cholesterol at a to Voriconazole had no effect on of CYP46A1 mRNA (Fig. or HMG-CoA (Fig. was a effect on the HMG-CoA reductase mRNA levels (Fig. The latter is with the effect of voriconazole on the brain levels of and lathosterol. The level of voriconazole in the brain of the mice after five daily intraperitoneal injections (60 mg/kg was corresponding to of brain levels of voriconazole after a (60 is in 6. In the present study, we tested antifungal azoles that are used systemically and three that are known to be expressed in the brain. we that voriconazole binds with high to CYP46A1 in vitro and inhibits cholesterol in the reconstituted in with this finding and the that voriconazole can the blood-brain we a in 24S- hydroxycholesterol levels in the brain in mice injected intraperitoneally with voriconazole for 5 We also observed a in the levels of 24S-hydroxycholesterol in the are two different for the reduced levels of 24S-hydroxycholesterol in the brain of the treated The is a inhibition of the enzyme by voriconazole. The high levels of voriconazole measured in the brain are in with The possibility is to the that voriconazole is an inhibitor of cholesterol synthesis. been that voriconazole its antifungal effect inhibition of cytochrome P450 which is responsible for the of in the L. 2003; Full Text PDF PubMed Scopus Google Scholar). a reduced of the brain cholesterol may to a reduced substrate for CYP46A1 and reduced of 24S-hydroxycholesterol. These two voriconazole may inhibit the of 24S-hydroxycholesterol are in The reduced levels of cholesterol and lathosterol as as HMG-CoA reductase mRNA that brain cholesterol was reduced in the voriconazole-treated The that the had no effect on the of the of cholesterol in the brain the that reduced substrate is of importance for the reduced of 24S-hydroxycholesterol. A effect of voriconazole on CYP46A1 can be expected to to a reduced of brain cholesterol a reduced for synthesis. the reduced of had been the most a of HMG-CoA reductase mRNA have been In this is of that a gene of CYP46A1 in mice is with a of cholesterol by about E.G. Xie C. Kotti T. Turley S.D. Dietschy J.M. Russell D.W. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover.J. Biol. Chem. 2003; 278: 22980-22988Abstract Full Text Full Text PDF PubMed Scopus (281) Google Scholar). The of the HMG-CoA reductase gene is by binding and we had expected a effect on of HMG-CoA to demonstrate this may be to the that may be to a of 24S-hydroxycholesterol to of from rat was also to significantly the level of HMG-CoA Y. S. J. The effect of 24S-hydroxycholesterol on cholesterol homeostasis in changes to the Res. 2008; PubMed Scopus Google Scholar). of cholesterol are in and the were carried out in the of cholesterol be These conditions are different from of in and the levels of transcriptional factors may be different in with voriconazole represents a model for inhibition of CYP46A1 than the voriconazole may be used for studies on the relation CYP46A1 activity and cholesterol In is to the of inhibition of the enzyme by of the 24S-hydroxycholesterol in the brain. One of the most effects of voriconazole is visual disturbances. Because CYP46A1 is expressed in the neural as L. Diczfalusy U. Björkhem I. M.A. L. C. N. A. C. (CYP46A1) is expressed in of the neural Res. PubMed Scopus Google Scholar, Andersson S. Russell D.W. and of cholesterol 24-hydroxylase in the 2008; PubMed Scopus Google the possibility may be that the visual are to an the drug and CYP46A1. this is the visual be expected in CYP46A1 gene with this in the have recently been in mice on a relation and cholesterol 24S-hydroxylase is in
23
PREPARATION OF LIPIDE EXTRACTS FROM BRAIN TISSUE
Jordi Folch, I. Ascoli, Marjorie B. Lees et al. · Journal of Biological Chemistry · 1951 · 1.3K citations · Full text
Ingemar Björkhem, Dieter Lütjohann, Ulf Diczfalusy et al. · Journal of Lipid Research · 1998 · 541 citations · Full text